In-vitro activity of fosfomycin against Escherichia coli and Klebsiella pneumoniae bloodstream isolates and frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant groups

dc.authoridZarakolu, Pınar/0000-0003-4918-4085
dc.authoridGurpinar Tosun, Oznur/0000-0002-2855-2961
dc.authoridAkalin, Halis/0000-0001-7530-1279
dc.authoridOtlu, Baris/0000-0002-6220-0521
dc.authoridKoksal, Iftihar/0000-0003-4892-8935
dc.authoridUnal, Serhat/0000-0003-1184-4711
dc.authoridOzakin, Cuneyt/0000-0001-5428-3630
dc.authorwosidZarakolu, Pınar/KEH-6744-2024
dc.authorwosidKoksal, Iftihar/B-7518-2016
dc.authorwosidAkalin, Halis/AAU-8952-2020
dc.contributor.authorZarakolu, Pinar
dc.contributor.authorEser, Ozgen Koseoglu
dc.contributor.authorOtlu, Baris
dc.contributor.authorGurpinar, Oznur
dc.contributor.authorOzakin, Cuneyt
dc.contributor.authorAkalin, Halis
dc.contributor.authorKoksal, Iftihar
dc.date.accessioned2024-08-04T20:50:41Z
dc.date.available2024-08-04T20:50:41Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aim of this study was to determine the in-vitro activity of fosfomycin against Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates and the frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant (CR) groups. A total of 346 isolates (126 E. coli and 220 K. pneumoniae) from nosocomial bloodstream infections were included. Carbapenem and fosfomycin susceptibility were tested by Etest (bioMerieux, France) and agar dilution methods, respectively and evaluated in accordance with EUCAST criteria. The presence of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases were conducted by using PCR method. Of the total 346 isolates, 185 (41 E. coli, 144 K. pneumoniae) were CR. Fosfomycin susceptibility of E. coli was higher than 95% and was not statistically significant between the CR and carbapenem-susceptible (CS) groups. Fosfomycin susceptibility of CS and CR K. pneumoniae was 90.7% and 69.4%, respectively, and statistically significantly lower in CR group. Of the total 185 CR isolates, 163 (32 E. coli, 131 K. pneumoniae) were producing carbapenemases. OXA-48 was the prominent carbapenemase type produced by E. coli (96.8%) and K. pneumoniae (70.9%). The frequency of NDM and KPC types produced by K. pneumoniae was 20.6% and 15.2%, respectively. Fosfomycin has substantial in-vitro activity against nosocomial CS and CR E. coli and CS K. pneumoniae bloodstream isolates. However, due to the risk of emerging resistance with fosfomycin monotherapy, combination therapy should be considered to obtain the possible additive or synergistic activity. Emerging fosfomycin resistance of CR K. pneumoniae isolates is alarming and OXA-48 is still the prominent carbapenemase type in Turkey.en_US
dc.identifier.doi10.1080/1120009X.2021.1963618
dc.identifier.endpage240en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue4en_US
dc.identifier.pmid34495816en_US
dc.identifier.scopus2-s2.0-85114643016en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage235en_US
dc.identifier.urihttps://doi.org/10.1080/1120009X.2021.1963618
dc.identifier.urihttps://hdl.handle.net/11616/100198
dc.identifier.volume34en_US
dc.identifier.wosWOS:000693960700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFosfomycin resistanceen_US
dc.subjectbloodstream infectionen_US
dc.subjectcarbapenem resistanceen_US
dc.subjectOXA-48en_US
dc.subjectNDMen_US
dc.subjectKPCen_US
dc.subjectVIMen_US
dc.subjectIMPen_US
dc.titleIn-vitro activity of fosfomycin against Escherichia coli and Klebsiella pneumoniae bloodstream isolates and frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant groupsen_US
dc.typeArticleen_US

Dosyalar